Arun Gupta, MD
Addiction Medicine · Monroe, MINPI 1841225166
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,493 and has fallen 56.5% since, to $650 in 2025. Among addiction medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$973
- Johnson & Johnson$757
- Neurocrine Biosciences, Inc.$419
- Boston Scientific$372
- Novo Nordisk$366
- Otsuka America Pharmaceutical, Inc.$344
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,495100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $973 |
| Johnson & Johnson | 16 | $757 |
| Neurocrine Biosciences, Inc. | 6 | $419 |
| Boston Scientific | 9 | $372 |
| Novo Nordisk | 24 | $366 |
| Otsuka America Pharmaceutical, Inc. | 11 | $344 |
| Novartis | 3 | $222 |
| Orexo US, Inc. | 10 | $195 |
| Abbott | 3 | $194 |
| Indivior Inc. | 6 | $180 |
| Alkermes, Inc. | 2 | $169 |
| Amgen | 7 | $147 |
| Sanofi | 1 | $122 |
| Lilly USA, LLC | 7 | $115 |
| Teva Pharmaceuticals USA, Inc. | 4 | $108 |
| Pfizer | 5 | $87 |
| Sanofi Pasteur Inc. | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 3 | $75 |
| Amarin Pharma, Inc. | 4 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Eisai Inc. | 2 | $45 |
| AstraZeneca | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| GSK | 3 | $38 |
| USWM, LLC | 2 | $37 |
| Acclarent, Inc | 1 | $34 |
| Lundbeck LLC | 2 | $27 |
| Alcon | 1 | $21 |
| Bayer | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Gilead | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$488
- INGREZZA$372
- XARELTO$241
- VRAYLAR$215
- Confirm Rx$142
- Mavyret$125
- REXULTI$122
- ARISTADA INITIO$122
- ENTRESTO$118
- SUBLOCADE$107
How this compares
$5,495 in reported general payments places this provider in the 90th percentile of 62 addiction medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 679 | $66,990 |
| EliquisApixaban | 54 | $43,844 |
| JanuviaSitagliptin Phosphate | 40 | $39,933 |
| MounjaroTirzepatide | 29 | $30,539 |
| OzempicSemaglutide | 18 | $28,018 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 117 | $25,936 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $22,851 |
| VraylarCariprazine Hcl | 11 | $15,145 |
| RybelsusSemaglutide | 11 | $12,955 |
| JardianceEmpagliflozin | 15 | $12,246 |
| BelbucaBuprenorphine Hcl | 14 | $11,673 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 37 | $10,844 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $10,243 |
| Repatha SureclickEvolocumab | 20 | $10,038 |
| LantusInsulin Glargine,hum.Rec.Anlog | 21 | $4,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $43,84454 claims |
| Novo NordiskOzempic, Rybelsus | $366 | $40,97329 claims |
| MerckJanuvia | $11 | $39,93340 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $38 | $33,09453 claims |
| Lilly USA, LLCMounjaro | $115 | $30,53929 claims |
| Orexo US, Inc.Zubsolv | $195 | $25,936117 claims |
| AbbVieVraylar | $973 | $15,14511 claims |
| Indivior Inc.Suboxone | $180 | $10,84437 claims |
| Sanofi-aventis U.S. LLCLantus | $47 | $4,58921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 addiction medicine providers in Michigan.
Other addiction medicine in Monroe
- Alta DerooKalamazoo$53K
- Michael FoxLivonia$39K
- William MorroneEssexville$17K
- Timothy GammonsSterling Heights$9K
- John CampbellKentwood$8K
- Morgan FoxLivonia$5K
- Jaswant BaggaAuburn Hills$4K
- Robert McMorrowHoughton Lake$3K
- Yasmin KeshavjeeWarren$3K
- Eric CoffmanBloomfield$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.